Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05674188 · ClinicalTrials.gov registry record · NA
AR vs In Person Simulation for Medical Workplace Training
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 111
- Enrollment target
NCT05674188: Completed NA study, sponsored by Stanford University.
NCT05674188 is a NA study that has completed, run by Stanford University. The registered enrollment target is 111 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05674188, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 111 participants
- Enrollment target
Study Summary
This study will evaluate the physiologic and emotional effects of an augmented reality (AR) simulation versus an in-person simulation. This is a single institution, non-inferiority, randomized controlled trial. The target enrollment will be 100 participants in each group for a total of 200 participants. One group will wear an AR headset and participate in an AR medical crisis scenario and the other group will participate in the same scenario with a traditional, mannequin based in situ simulation.
Primary Outcome
Measured via respiratory sinus arrhythmia (RSA) in hertz using chest biometric sensors in 30-second epochs.
Interventions
- BEHAVIORAL Augmented Reality Headset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2023-03-22 |
| Phase | NA |
What the finished NCT05674188 record still lists
NCT05674188 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Augmented Reality Headset is the first listed.
NCT05674188 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05674188 about?
NCT05674188 is a clinical study titled "AR vs In Person Simulation for Medical Workplace Training". This study will evaluate the physiologic and emotional effects of an augmented reality (AR) simulation versus an in-person simulation. This is a single institution, non-inferiority, randomized controlled trial. The target enrollment will be 100 participants in each group for a total of 200 participa...
What is the current status of trial NCT05674188?
This trial is currently completed. It is a NA study. The enrollment target is 111 participants. The study started on 2023-03-20. Estimated completion is 2023-03-22.
What interventions are being tested in trial NCT05674188?
The interventions under investigation include: Augmented Reality Headset (BEHAVIORAL).
Who is sponsoring clinical trial NCT05674188?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05674188's enrollment target sits among peer trials
111 816th of 2000 higher than 1,185 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI